Smt. Kanuri Santhamma Center for Vitreoretinal Diseases; Sudhakar and Shreekanth Ravi Stem Cell Biology Laboratory, Prof. Brien Holden Eye Research Center, LV Prasad Eye Institute, Hyderabad, Telangana, India.
Sudhakar and Shreekanth Ravi Stem Cell Biology Laboratory, Prof. Brien Holden Eye Research Center, LV Prasad Eye Institute, Hyderabad, Telangana, India.
Indian J Ophthalmol. 2019 Sep;67(9):1455-1458. doi: 10.4103/ijo.IJO_317_19.
The sub-retinal injections are not very commonly performed procedures in vitreoretina, but form a crucial step in any cell replacement therapy for retinal diseases. The purpose of this study is to describe the learning curve of a trained vitreo-retinal surgeon in sub-retinal injections in a rat model and its implications in future clinical trials.
This is an in-vivo retrospective animal study using Wistar rats. All ARVO guidelines regarding animal handling were followed. After anesthetization, aspectic preparation and dilating the pupils with 1% tropicamide eye drops, subretinal injection of 10 μl saline was done via a limbal entry. Data recorded included time taken for the procedure, success of injection, associated complications, post-operative infections and complications. The rats were followed up for 1 month post procedure. A trend analysis was done for the above factors to look for improvement in ease of procedure, reduction in procedure time and reduction in complications for the clinician using a novel objective scale.
About 20 eyes were studied. Mean weight of the rats was 188 ± 12.82 gram. Mean time taken for the procedure was 14.1 ± 5.07 minutes. There was a significant inverse co-relation between the serial number of the eye and time taken for the procedure (r = -0.89, P < 0.0001). Comparative complications noted between the first ten and the last ten eyes were: conjunctival tear 30% versus 10% (P = 0.27), lens touch 50% versus 10% (P = 0.05), subretinal hemorrhage 40% versus 0% (P = 0.13), vitreous loss 30% versus 0% (P = 0.06). The successful subretinal injection without intraocular complications was achieved in 40% versus 90% (P = 0.02). There was a significant co-relation between the serial number of the eye and ease of the procedure (r = 0.87, P < 0.0001). Post operatively none of the eyes had any infection. Six eyes (12%) developed cataract and 3 eyes (6%) had non-resolving retinal detachment at the last examination visit.
Subretinal injections in rats have a definite learning curve even for a trained vitreoretinal surgeon. This should be accounted for and resources allocated accordingly to achieve good technical comfort and negate confounding by the surgeon factor in the results of future clinical trials.
视网膜下注射在玻璃体视网膜手术中并不常见,但它是视网膜疾病细胞替代治疗中至关重要的一步。本研究的目的是描述一位训练有素的玻璃体视网膜外科医生在大鼠模型中进行视网膜下注射的学习曲线及其对未来临床试验的影响。
这是一项使用 Wistar 大鼠的体内回顾性动物研究。所有有关动物处理的 ARVO 指南均得到遵循。在麻醉、表面准备和 1%托吡卡胺滴眼剂散瞳后,通过角膜缘入口向视网膜下注射 10μl 生理盐水。记录的数据包括手术时间、注射成功率、相关并发症、术后感染和并发症。在手术后 1 个月对大鼠进行随访。使用一种新的客观量表对上述因素进行趋势分析,以寻找手术难度的降低、手术时间的缩短和并发症的减少。
大约对 20 只眼睛进行了研究。大鼠的平均体重为 188±12.82 克。手术平均时间为 14.1±5.07 分钟。手术次数与手术时间之间存在显著的负相关关系(r=-0.89,P<0.0001)。在前 10 只眼和后 10 只眼中观察到的比较性并发症为:结膜撕裂 30%对 10%(P=0.27),晶状体接触 50%对 10%(P=0.05),视网膜下出血 40%对 0%(P=0.13),玻璃体丢失 30%对 0%(P=0.06)。无眼内并发症的成功视网膜下注射成功率为 40%对 90%(P=0.02)。手术难度与手术次数之间存在显著的正相关关系(r=0.87,P<0.0001)。术后无感染发生。最后一次检查时,6 只眼(12%)出现白内障,3 只眼(6%)出现无法消退的视网膜脱离。
即使对于训练有素的玻璃体视网膜外科医生,大鼠的视网膜下注射也有明确的学习曲线。在未来的临床试验中,应该考虑到这一点,并相应地分配资源,以达到良好的技术舒适度,并消除手术医生因素对结果的干扰。